ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

NIH Plans Consensus Conference On Ovarian Cancer April 5-7

January 28, 1994

Research Funding In Crisis; Scientists Fear Cancer Program’s Dismantling, AACR Says

January 20, 1995

Triple-Negative Breast Cancer Equally Aggressive in Whites

February 25, 2011

Severe Shortages Of Many Cancer Drugs Affecting Practices

November 19, 2010

In Brief: Last Bit of Nonsense By Weinberger; Magnuson May Write NCI Positions Into HEW Money Bill

July 18, 1975

In Brief: Ma and Tyner Receive Award From AAAS

July 4, 2014